Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody
Open Access
- 2 March 2000
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 342 (9), 613-619
- https://doi.org/10.1056/nejm200003023420902
Abstract
Alloantigen-activated T cells express the high-affinity interleukin-2 receptor. Specific blockade of this receptor with the human IgG1 monoclonal antibody daclizumab may prevent rejection of allografts after cardiac transplantation without inducing global immunosuppression.Keywords
This publication has 20 references indexed in Scilit:
- Epitope spreadingCurrent Opinion in Immunology, 1996
- Indirect recognition of donor HLA-DR peptides in organ allograft rejection.JCI Insight, 1996
- MONITORING OF SOLUBLE HLA ALLOANTIGENS AND ANTI-HLA ANTIBODIES IDENTIFIES HEART ALLOGRAFT RECIPIENTS AT RISK OF TRANSPLANT-ASSOCIATED CORONARY ARTERY DISEASE1Transplantation, 1996
- Cardiac allograft vasculopathy: Current conceptsAmerican Heart Journal, 1995
- Risk/benefit ratio of perioperative OKT3 in cardiac transplantationThe American Journal of Cardiology, 1994
- Contribution of direct and indirect recognition pathways to T cell alloreactivity.The Journal of Experimental Medicine, 1993
- Do B cells drive the diversification of immune responses?Immunology Today, 1993
- The IL-2/IL-2 receptor system: A current overviewCell, 1993
- Multiple levels of peripheral toleranceImmunology Today, 1993
- A RANDOMIZED CLINICAL TRIAL OF INDUCTION THERAPY WITH OKT3 IN KIDNEY TRANSPLANTATIONTransplantation, 1993